Foretinib (GSK1363089) is an inhibitor of multiple receptor tyrosine kinases including MET and VEGFR, with the potential for treatment of solid tumors. In this study, we investigated the in vitro metabolic pathways for foretinib in rat liver microsomes using LC-MS/MS. Methoxylamine and potassium cyanide were used as trapping agents for aldehyde and iminium reactive intermediates, respectively, of foretinib to form a stable complex that can be identified by LC-MS/MS. Six foretinib phase I metabolites were characterized. The phase I metabolic pathways were oxidation, defluorination, reduction and hydroxylation. Additionally, four potential reactive metabolites, two aldehydes and two iminium ions, were found and the bioactivation pathways were proposed. Reporting the in vitro and reactive metabolites of foretinib is very crucial in the development stage. A literature review showed that no previous articles have provided an in vitro metabolism study of foretinib or detailed structural identification of the formed reactive metabolites.
Introduction
Tyrosine kinase inhibitors (TKIs) are considered a very important class of targeted therapy which interferes with specic cell signalling pathways that allow targeting selected malignancies.
1
Tyrosine kinases are enzymes that catalyze the transfer of the g phosphate of ATP to the tyrosine hydroxyl groups on target proteins. They act as an "on" or "off" switch in many cellular functions.
2 Strict control of the tyrosine kinase activity in the cell regulates important processes such as the cell cycle, proliferation and cell death. In many cases, the abnormal proliferation characteristics of cancer are driven by growth factor receptor-mediated signaling. In tumor cells, the failure of the control mechanism may lead to excessive phosphorylation, and pathways sustained in an activated state. 3, 4 Foretinib is a multikinase inhibitor that inhibits multiple receptor tyrosine kinases, including MET (mesenchymal-epithelial transition factor) and VEGFR (vascular endothelial growth factor receptor-2), with the potential for treatment of solid tumors 5 and hepatocellular carcinoma (HCC). 6 Foretinib showed a very promising synergetic effect with HER2 inhibitors and the potential to overcome drug resistance to lapatinib. 7 Metabolic activation of a drug leading to reactive metabolite(s) that can covalently modify proteins is considered an initial step that may lead to drug-induced organ toxicities.
Metabolism is considered a detoxication process by which endogenous compounds and xenobiotics are transformed into more hydrophilic species to enable elimination from the body. In most cases, metabolites are less toxic than parent molecules, but sometimes undergo bioactivation to form reactive intermediates that are more toxic. [8] [9] [10] Reactive metabolites can covalently modify proteins, which are considered the rst step in druginduced organ toxicities. 11, 12 The reactive metabolites generated from metabolism are considered crucial in drug-induced toxicity. Usually, reactive metabolites are produced by phase I metabolic reactions. The reactive metabolites can cause many side effects. Reactive intermediates cannot be detected directly due to their transient nature. Instead, a trapping agent was used to capture the reactive intermediate, leading to formation of adducts which are stable and can be detected and characterized by tandem mass spectrometry.
Foretinib chemical structure contains morpholine group (Fig. 1) . Morpholine group containing drugs undergo bioactivation by iminium ion formation or oxidative dealkylation to form aldehyde. [15] [16] [17] GSH or its derivatives are not suitable agents for trapping hard reactive intermediates. Potassium cyanide (KCN) and methoxyl amine are considered perfect trapping agents for iminium ion and aldehydes intermediates, respectively. 8, 15, 16 The formed adducts are stable and can be separated, detected and characterized using liquid chromatography tandem mass spectrometry. [13] [14] [15] 18, 19 2. Chemicals and methods
Chemicals
Foretinib was procured from LC Labs (Woburn, MA, USA). Ammonium formate and HPLC-grade acetonitrile (ACN), potassium cyanide (KCN), methoxyl amine (MeONH 2 ) and formic acid were procured from Sigma-Aldrich (West Chester, PA, USA). Puried water was obtained from Milli-Q plus purication system, Millipore, Waters (Millipore, Bedford, MA, USA). Rat liver microsomes (RLMs) were prepared in-house using Sprague Dowley rat following reported method. 20 
Chromatographic conditions
Study of foretinib fragmentation was performed using an Agilent HPLC 1200 connected to triple quadrupole mass spectrometer (Agilent 6410 QqQ) by direct injection through using a connector instead of a column. Chromatographic separation for extract of the incubation mixture was performed on an Agilent 1200 series system and an Agilent 6410 QqQ LC/MS with an electrospray ionization (ESI) interface. The chromatography was performed on Agilent eclipse plus C 18 analytical column (150 mm Â 2.1 mm, 3.5 mm particle size) (Agilent Technologies, Palo Alto, CA, USA). Column temperature was kept constant at 25 AE 2 C. The most suitable chromatographic conditions were achieved at a ow rate of 0.25 mL min À1 with a gradient system. Mobile phase consisted of solvent A which is 10 mM ammonium formate (pH: 4.2 by addition of formic acid) and solvent B which is ACN. The stepwise gradient was 5% B (0-5 min), 5 to 70% B (5-60 min), 70 to 90% B (60-70 min), 90 to 5% B (70-75 min). The post time was 15 minutes to allow conditioning of column before the next run.
Sample injection volume was 15 mL with a total run time of 75 minutes. Mass parameters were optimized for foretinib. Product ions for foretinib, its phase I metabolites and its adducts were generated in the collision cell by collision-induced dissociation (CID) mode. Detection was performed on a triple quadrupole mass spectrometer, operated with an ESI interface in the positive ionization mode. Low purity nitrogen was used as desolvation gas at a ow rate of 12 L min À1 and high purity nitrogen was used as collision gas at a pressure of 55 psi. Source temperature was set at 350 C and capillary voltage was set at 4000 V. Fragmentor voltage was set to 145 V with collision energy of 25 eV for foretinib, its phase I metabolites and its adducts. Mass Hunter soware (Agilent Technologies, Palo Alto, CA, USA) was used to control the instruments and data acquisition.
RLMs incubations
Thirty mM foretinib was incubated with 1.0 mg mL À1 RLMs, 1.0 mM NADPH and 50 mM Na/K phosphate buffer (pH 7.4) containing 3.3 mM MgCl 2 . The mixtures were incubated at 37 C in a shaking water bath for 120 min. The metabolic reaction was initiated by addition of NADPH and terminated by adding 2 mL of ice-cold ACN. Centrifugation for the incubation mixture (14 000 rpm, 10 min and 4 C) was done to devoid of proteins. The supernatants were removed, evaporated and reconstituted in ACN/ water and transferred to HPLC vial to be injected into Agilent 6410 LC-MS.
21,22
2.4. Trapping foretinib reactive metabolites using methoxylamine and potassium cyanide
The same experiment of RLMs incubation was repeated using 2.5 mM methoxyl amine and with 1.0 mM KCN to capture reactive iminium and aldehyde intermediates. Incubations were performed in triplicate to conrm the data obtained.
Identication of the in vitro foretinib metabolites
Full mass spectra (MS) scan and product ion (PI) experiment were used to detect of metabolites and adducts of foretinib formed by the in vitro incubations with RLMs. Searching for metabolites in the total ion chromatogram (TIC) of the metabolic extract was done by extracted ion chromatogram (EIC) of m/z of proposed foretinib metabolites. EICs of the metabolic extract were compared with control incubations.
Results and discussion

PI study of foretinib
Foretinib molecular ion peak (MIP) appears as [M + H] + (m/z 633)
at 40.9 min in PI chromatogram ( Fig. 2A) . Collision induced dissociation (CID) of parent ion at m/z 633 gave two daughter ions (DI) at m/z 128 and at m/z 100 (Fig. 2B ). DI at m/z 128 represents propyl morpholine ring by single bond cleavage (Scheme 1).
Identication of in vitro foretinib metabolites produced RLMs incubation
Puried extracts of RLMs incubations were injected into LCQqQ. Metabolites were not observed in control incubations. Five phase I metabolic reactions generated six metabolites through: a hydroxylation, a oxidation, reduction, ether cleavage and deourination. Two cyano adducts and two methoxyl amine conjugates were characterized aer incubation with RLMs in the presence of 1.0 mM KCN and 2.5 mM methoxylamine, respectively ( (Fig. 3A) . CID of parent ion at m/z 649 gave one DI at m/z 144 which represent propyl hydroxyl morpholine ring by single bond cleavage (Fig. 3B) . Hydroxylation was proposed to happen in a position of morpholine nitrogen atom (Scheme 2). chromatogram (Fig. 5A) . CID of parent ions at m/z 635 gave different DIs. In case of FA635a, CID gave two DIs at m/z 128 and at m/z 100 (Fig. 5B ). DI at m/z 128 proposed that no metabolic change occurred in the morpholine ring. DIs revealed that FA635a is reduced form of foretinib without any metabolic change at morpholine ring (Scheme 4).
In case of FA635b, CID gave three DIs at m/z 506, at m/z 130 and at m/z 74 (Fig. 5C ). DI at m/z 130 proposed that metabolic change occurred in the morpholine ring which is consistent (Fig. 6A) . CID for FA615a and FA615b gave DI at m/z 128 ( Fig. 6B and C) which represent propyl morpholine ring by single bond cleavage. DI at m/z 128 proposed that no metabolic change occurred in the morpholine ring. The DIs revealed that the metabolic reaction for FA615a and FA615b is deouri-nation of one our atom at two different positions (Scheme 6).
Identication of in vitro foretinib reactive metabolites
Two methoxyl adducts and two cyano conjugates were detected in the case of incubation of foretinib with RLMs and 2.5 mM methoxylamine and 1.0 mM KCN, respectively. containing drugs (cyclic tertiary amine ring), 23,24 a carbon of the N atom of morpholine ring was proposed to be bioactivated and attacked by cyanide ion (Scheme 7).
Identication of FC660 cyano conjugate of foretinib. FC660 MIP appears as [M + H]
+ (m/z 660) at 51.0 min in PI chromatogram (Fig. 8A) . CID of parent ion at m/z 660 gave DIs at (Fig. 10B) . The DI at m/ z 506 proposed the formation of oxime and all metabolic reactions occurred in propyl morpholine ring. The DI at m/z 102 proposed hydroxylation of propyl carbon which is consistent with the other DI at m/z 327 (Scheme 10).
Proposed pathways of bioactivation of foretinib
The formation of FC558 and FC660 cyanide conjugates indicated that the formation of iminium intermediates in the morpholine ring. KCN is the perfect trapping agent for iminium. 25 Hydroxylation of morpholine ring in foretinib then dehydration resulted in formation of iminium ions that are not stable but can be trapped by cyanide forming stable adduct that can be detected in LC-MS/MS (Scheme 11). The pathway of formation of iminium intermediate and foretinib bioactivation is previously described with cyclic tertiary amine containing drugs.
21,22
The formation of FM591 and FM607 indicated that their aldehyde intermediates were generated in the metabolism of foretinib. The aldehyde (FM591) was generated by dealkylation and trapped with methoxylamine to form oxime FM607 was produced in two steps. Foretinib was rst hydroxylated then underwent dealkylation to generate aldehyde which was trapped by methoxylamine to form oxime. Both oximes were stable and characterized using LC-MS/MS (Scheme 12). The pathway for formation of aldehyde was described with a morpholine group containing drugs. 
Conclusions
Six phase I foretinib metabolites in addition to four potential reactive metabolites, two aldehydes and two iminium ions, were detected and the bioactivation pathways were proposed Scheme 10 Proposed CID of FM607.
Scheme 11 Proposed pathway of the formation of iminium intermediates and trapping strategy. ( Fig. 11 ). These reactive metabolites may be the reason of foretinib side effects as they are the rst step in drug-induced organ toxicities. 11, 12 This study illuminates the way for further work in the foretinib development and approving to be used in the clinic. 
